Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q1 2026 earnings summary

Executive summary

• Q1 2026 was marked by significant operational and financial pressures, including drug supply shortages and cash flow challenges, prompting management to launch turnaround initiatives and creditor negotiations.

• Gross revenue reached R$6.1 billion in LTM 1Q26, up 1.2% sequentially, but net revenue and profitability were pressured by higher provisions for doubtful accounts and medication shortages.

• Adjusted EBITDA for LTM 1Q26 was R$627.9 million, but for 1Q26 turned negative at R$49.2 million, reflecting operational disruptions and increased provisions.

• Net income was negatively impacted by lower operating leverage, accounting adjustments, and a net loss of R$438.7 million in 1Q26.

• Despite challenges, fundamentals remain solid and national leadership in oncology is maintained.

Financial highlights

• Revenue was negatively impacted by a BRL 40 million shortfall due to medication shortages, resulting in about 4,000 fewer procedures in Q1.

• Average ticket price increased 4.8% quarter-over-quarter and 14.3% year-over-year, reflecting improved commercial negotiations and payer mix.

• Net revenue for LTM 1Q26 was R$5.4 billion, but for 1Q26 was R$1,160.8 million, down 22.3% year-over-year.

• Adjusted EBITDA margin declined to 11.2% in 1Q26 from 15.1% in 1Q25, and normalized EBITDA margin dropped from 11.2% to 8.7%.

• Net loss for 1Q26 was R$438.7 million, compared to a net loss of R$132.0 million in 1Q25.

Outlook and guidance

• Operational and financial recovery will be gradual, with transparency and ongoing market updates promised.

• Management is focused on operational turnaround, cost reduction initiatives, and may pursue inorganic strategies to restore profitability.

• Debt rescheduling discussions with creditors are underway to align amortization with cash generation.